Lung cancer andCYP1A1 orGSTM1 polymorphisms.
- Author:
Tsunehiro OYAMA
1
;
Norio KAGAWA
;
Yong-Dae KIM
;
Akiko MATSUMOTO
;
Toyohi ISSE
;
Toshihiro KAWAMOTO
Author Information
- Publication Type:Journal Article
- Keywords: Cytochrome p4501A1 gene (CYP1A1) polymorphism; glutathione S-transferase μ gene (GSTM1) polymorphism; non-small-cell lung cancer (NSCLC); p53 gene mutation; survival curve
- From:Environmental Health and Preventive Medicine 2003;7(6):230-234
- CountryJapan
- Language:English
- Abstract: Most chemical carcinogens are metabolized and activated in vivo by phase I enzymes including the microsomal cytochromes P450 and epoxide hydroxylases. The carcinogens and their metabolites are detoxified by phase II enzymes that in clude various transferases such as glutathion-S-transferases (GST). Increasing numbers of studies have demonstrated the association of the polymorphisms inGSTM1 (a member of GST) andCYP1A1 genes with the susceptibility to lung cancer. Subsequently, the polymorphisms appear to be important biomarkers that provide information for assessment of exposure and total burden of environmental carcinogens. Therefore, the investigation of the polymorphisms in these genes will provide information not only for the prediction of individual cancer risk but also for the prevention of cancer. In this review, we will summarize the polymorphisms in theGSTM1 andCYP1A1 genes and their relation to lung cancer susceptibility.
